Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Other Non-Current Assets came in at $14.3 billion in Q2 2026, up 17.06% year-over-year from $12.2 billion in Q2 2025, and up 1.16% quarter-over-quarter from $14.1 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $14.3 billion for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 17.06% year-over-year to $14.3 billion; the TTM figure through Jun 2026 stood at $14.3 billion (up 17.06% YoY), while the FY2025 annual figure was $14.4 billion, up 25.88% from the prior year.
- Other Non-Current Assets came in at $14.3 billion for Q2 2026 at Johnson & Johnson, up from $14.1 billion in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $27.2 billion in Q1 2023 to a low of $8.6 billion in Q4 2022.
- Average Other Non-Current Assets over 5 years is $12.5 billion, with a median of $11.5 billion recorded in 2025.
- The largest YoY upside for Other Non-Current Assets was 166.61% in 2023 against a maximum downside of 48.04% in 2023.
- Over 5 years, Other Non-Current Assets stood at $8.6 billion in 2022, then surged by 64.09% to $14.2 billion in 2023, then fell by 19.35% to $11.4 billion in 2024, then grew by 25.88% to $14.4 billion in 2025, then slipped by 0.69% to $14.3 billion in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $14.3 billion in Q2 2026, $14.1 billion in Q1 2026, and $14.4 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 9.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 6.38 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 5.50 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 42.45 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 109.58 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 86.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 14.27 Bn |
| Mar 29, 2026 | 14.11 Bn |
| Dec 28, 2025 | 14.37 Bn |
| Sep 28, 2025 | 12.42 Bn |
| Jun 29, 2025 | 12.19 Bn |
| Mar 30, 2025 | 11.53 Bn |
| Dec 29, 2024 | 11.41 Bn |
| Sep 29, 2024 | 10.92 Bn |
| Jun 30, 2024 | 10.54 Bn |
| Mar 31, 2024 | 14.13 Bn |
| Dec 31, 2023 | 14.15 Bn |
| Oct 1, 2023 | 13.13 Bn |
| Jul 2, 2023 | 10.08 Bn |
| Apr 2, 2023 | 9.57 Bn |
| Jan 1, 2023 | 27.24 Bn |
| Oct 2, 2022 | 8.63 Bn |
| Jul 3, 2022 | 9.44 Bn |
| Apr 3, 2022 | 9.94 Bn |
| Jan 2, 2022 | 10.22 Bn |
| Oct 3, 2021 | 6.87 Bn |